0 11

Cited 0 times in

Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea

 Kyong Joo Lee  ;  Jae Hee Cho  ;  Sang Hyub Lee  ;  Si Young Song  ;  Kwang Hyuk Lee  ;  Seok Jeong  ;  Ji Kon Ryu  ;  Sang Myung Woo  ;  Seungmin Bang  ;  Jong Kyun Lee  ;  Tae Hoon Lee  ;  Woo Hyun Paik  ;  Yong Tae Kim  ;  Woo Jin Lee 
 Cancer Chemotherapy and Pharmacology, Vol.80(4) : 799-805, 2017 
Journal Title
 Cancer Chemotherapy and Pharmacology 
Issue Date
Adult ; Aged ; Aged, 80 and over ; Anemia/chemically induced ; Anemia/epidemiology ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use* ; Disease-Free Survival ; Everolimus/adverse effects ; Everolimus/therapeutic use* ; Exanthema/chemically induced ; Exanthema/epidemiology ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Grading ; Neoplasm Recurrence, Local ; Pancreatic Neoplasms/drug therapy* ; Pancreatic Neoplasms/pathology ; Prognosis ; Republic of Korea ; Retrospective Studies ; Stomatitis/chemically induced ; Stomatitis/epidemiology ; Treatment Outcome ; Young Adult
Everolimus ; Pancreatic neuroendocrine tumor ; Prognosis ; Tumor grade ; World Health Organization classification
PURPOSE: Everolimus is a standard treatment option for advanced pancreatic neuroendocrine tumors (pNETs). This multicenter study evaluated the efficacy and safety of everolimus in low and intermediate grade advanced pNETs. METHODS: Tumors were graded according to the World Health Organization 2010 classification system. Patients with low or intermediate grade pNETs who received everolimus as first- or second-line chemotherapy between 2002 and 2014 were included. RESULTS: A total of 40 patients with metastatic or recurrent pNETs were included in this study. The median age was 54.5 years (range 19-83 years). Twelve patients (30%) experienced recurrence. There were 11 patients (27.5%) with low grade pNETs and 29 (72.5%) with intermediate. Everolimus was administered as first-line therapy in 30 patients (75%) and as second-line therapy in 10 patients (25%). The median progression-free survival (PFS) of patients with low and intermediate grade pNETs was significantly different (median not reached vs. 11 months, P = 0.015). On multivariate analysis, tumor grade (intermediate grade; HR 6.52, 95% CI 1.31-32.27, P = 0.022) was the only independent prognostic factor for PFS in pNETs. The most common adverse events were stomatitis, skin rash, and anemia. CONCLUSIONS: World Health Organization 2010 grade is the most important determinant for PFS in patients undergoing everolimus treatment for pNETs with an acceptable incidence of adverse events.
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
Yonsei Authors
방승민(Bang, Seungmin) ; 송시영(Song, Si Young)
사서에게 알리기
Full Text
RIS (EndNote)
XLS (Excel)


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.